http://sunnybrook.ca/media/item.asp?c=1&i=508 "The RESCUE study demonstrated that more continuous treatment with the drug Temodal (TMZ) is a valuable therapeutic option for patients with recurrent glioblastoma multiforme (GBM)," says Dr. James Perry, Head of the Division of Neurology at Sunnybrook. "The trial results showed an increase in both six-month and one-year progression-free survival of patients undergoing chemotherapy, with excellent tolerability of the dosage, and minimal side effects."
very inspiring, patients can breath now for this very inspiring message
gadionson1 3 months ago